Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1739-1748

  Shah, Nisha V ^a   Houston, Samuel K ^a   Markoe, Arnold M ^b   Feuer, William ^c   Murray, Timothy G ^a,b,d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d Murray Ocular Oncology and Retina   (United States)

Author keywords

BCVA; Intravitreal bevacizumab; Plaque brachytherapy; Radiation maculopathy; Uveal melanoma

Indexed keywords

BEVACIZUMAB; IODINE 125;

ADULT; ARTICLE; BRACHYTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; RADIATION INJURY; RECURRENT DISEASE; RETINA MACULOPATHY; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; UVEA MELANOMA; VISUAL ACUITY;

EID: 84869209056     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S34949     Document Type: Article

References (55)

1. Hawkins BS. Collaborative Ocular Melanoma Study randomized trial of I-125 brachytherapy. Clin Trials. 2011;8(5):661-673.
2. Melia BM, Abramson DH, Albert DM, et al. Collaborative ocular melanoma study (COMS) randomized trial of 1-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report No. 16. Ophthalmology. 2001;108:348-366.
3. Giuliari G, Sadaka A, Hinkle D, et al. Current treatments for radiation retinopathy. Acta Oncologica. 2011;50:6-13.
4. Jampol LM, Moy CS, Murray TG, Reynolds SM, et al. Collaborative Ocular Melanoma Study Group (COMS Group). The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. COMS report no. 19. Ophthalmology. Dec 2002;109(12):2197-2206.
5. Finger PT, Chin KJ, Duvall G, Palladium-103 for Choroidal Melanoma Study Group. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology. 2009;116:790-796.
6. Krema H, Somani S, Sahgal A, Xu W, Heydarian M, Payne D. Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up. Br J Ophthalmol. 2009;93:1172-1176.
7. Gragoudas ES, Seddon JM, Egan K, Glynn R, Munzenrider J, Austin-Seymour M. Long-term results of proton beam irradiated uveal melanomas. Ophthalmology. 1987;94:349-353.
8. Haas A, Pinter O, Papaefthymiou G, Weger M, Berghold A, Schrottner O. Incidence of radiation retinopathy after high-dosage single-fraction gamma knife radiosurgery for choroidal melanoma. Ophthalmology. 2002;109:909-913.
9. Levy RP, Fabrikant JI, Frankel KA, Phillips MH, Lyman JT, Lawrence JH. Heavy-charged-particle radiosurgery of the pituitary gland: Clinical results of 840 patients. Stereotact Funct Neurosurg. 1991;57:22-35.
10. Houston SK 3rd, Markoe AM, Boldt HC, Murray TG. Juxtapapillary uveal melanomas: patient outcomes after treatment with proton irradiation for peripapillary and parapapillary melanomas. Arch Ophthalmol. Sep 2011;129(9):1218-1220.
11. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119:969-982.
12. Archer DB, Amoaku WM, Gardiner TA. Radiation retinopathy clinical, histopathological, ultrastructural and experimental correlations. Eye (Lond). 1991;51, 5(Pt 2):239-251.
13. Horgan N, Shields CL, Mashayekhi A, Teixeira LF, Materin MA, Shields JA. Early macular morphological changes following plaque radiotherapy for uveal melanoma. Retina. 2008;28:263-273.
14. Brown GC, Shields JA, Sanborn G, Augsburger JJ, Savino PJ, Schatz NJ. Radiation retinopathy. Ophthalmology. 1982;89:1494-1501.
15. Bosworth JL, Packer S, Rotman M, Ho T, Finger PT. Choroidal melanoma: I-125 plaque therapy. Radiology. 1988;169:249-251.
16. Massin P, Erginay A, Haouchine B, et al. Retinal thickness in healthy and diabetic subjects measured using optical coherence tomography mapping software. Eur J Ophthal. 2002;12:102-108.
17. Catier A, Tadayoni R, Paques M, et al. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthal. 2005;140:200-206.
18. Toth CA, Narayan DG, Boppart SA, et al. A comparison of retinal morphology viewed by optical coherence tomography and by light microscopy. Arch Ophthal. 1997 Nov;115 (11):1425-8.
19. Levitz LM. The use of optical coherence tomography to determine the severity of radiation retinopathy. Ophthalmic Surg Laswers Imaging. 2005;36:410-411.
20. Coker JG. Duker JS. Macular disease and optical coherence tomography. Curr Opin Ophthal. 1996;7:33-38.
21. Mukai SGD, Gragoudal ES. Radiation retinopathy. In: Albert DM JF, ed. Principles and practice of ophthalmology. Vol 2. Philadelphia: WB Saunders. 1994:1038-1041.
22. Guyer DR, Mukai S, Egan KM, Seddon JM, et al. Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology. 1992;99:1278-1285.
23. Horgan N, Shields C, Mashayekhi, et al. Classification and treatment of radiation maculopathy. Current Opinion in Ophthalmology. 2010;21:233-238.
24. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. Jan 3 1990;82(1):4-6.
25. Boyd SR, Tan D, Bunce C, Gittos A, et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol. Apr 2002;86(4):448-452.
26. Missotten GS, Notting IC, Schlingemann RO, et al. Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol. Oct 2006;124(10):1428-1434.
27. Piña Y, Cebulla CM, Murray TG, et al. Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature. Ophthalmic Res. 2009;41(3):160-169.
28. Kim JH, Kim C, Kim JH, et al. Absence of intravitreal bevacizumab-induced neuronal toxicity in the retina. Neurotoxicology. Nov 2008;29(6):1131-1135.
29. Ijland SA, Jager MJ, Heijdra BM, Westphal JR, Peek R. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res. 1999;9:445-450.
30. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112;1048-1105.
31. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. Jun 2010;117(6):1102-1112.
32. Diabetic Retinopathy Clinical Research Network, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. Dec 2011;118(12):5-14.
33. Michaelides M, Fraser-Bell S, Hamilton R, et al. (Bolt Study): Report1. Retina. May 2010;30(5):781-786.
34. Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (bevacizumab) for radiation retinopathy. Arch Ophthalmol. Jun 2007;125(6):751-756.
35. Stack R, Elder M, Abdelaal A, Hidajat R, Clemett R. New Zealand experience of I125 brachytherapy for choroidal melanoma. Clin Experiment Ophthalmol. 2005;33:490-494.
36. Mason JO 3rd, Albert MA Jr, Persaud TO, Vail RS. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina. Sep 2007;27(7):903-907.
37. Gupta A, Muecke JS. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina. Jul-Aug 2008;28(7):964-968.
38. Finger PT, Mukkamala SK. Intravitreal anti-VEGF bevacizumab (Avastin) for external beam related radiation retinopathy. Eur J Ophthalmol. Jul 2011;21(4):446-451.
39. Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys. Mar 15 2008;70(4):974-977.
40. De Potter P, Shields CL, Shields JA, Cater JR, Brady LW. Plaque radiotherapy for juxtapapillary choroidal melanoma. Visual acuity and survival outcome. Arch Ophthalmol. 1996;114:1357-1365.
41. Char DH. Clinical ocular oncology, Churchill Livingstone, New York. 1989:117-121.
42. Shields JA, CL Shields Intraocular tumors, WB Saunders, Philadelphia. 1992:25-43.
43. Hui JI, Murray TG. Radioactive plaque therapy. Int Ophthalmol Clin. 2006;46(1):51-68.
44. Shah NV, Houston SK, Murray TG, Markoe AM. Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review. Clinical Ophthalmology. 2012:6(447-452).
45. Harbour JW, Murray TG, Byrne SF, et al. Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma. Retina. 1996;16(2):129-134.
46. Tabandeh H, Chaudhry NA, Murray TG, et al. Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am J Ophthalmol. Feb 2000;129(2):199-204.
47. Newman H, Chin KJ, Finger PT. Subfoveal Choroidal Melanoma Pretreatment Characteristics and Response to Plaque Radiation Therapy. Arch Ophthalmol. 2011;129(7):892-898.
48. Levy RL, Miller NR. Hyperbaric oxygen therapy for radiation-induced optic neuropathy. Ann Acad Med Singapore. Mar 2006;35(3):151-157.
49. Finger PT, Kurli M. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2005;89:730-738.
50. Kinyoun JL. Long term visual acuity results of treated and untreated radiation retinopathy (an AOS thesis). Trans Am Ophthal Soc. 2008;106:325-335.
51. Bakri SJ, Beer PM. Photodynamic therapy for maculopathy due to radiation retinopathy. Eye (Lond). 2005;19:795-799.
52. Sutter FK, Gillies MC. Intravitreal triamcinolone for radiation macular edema. Arch Ophthalmol. 2003;121:1491-1493.
53. Shields CL, Demirci H. Dai V, et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina. 2005;25:868-874.
54. Ziemssen F, Voelker M, Alpeter E, et al. Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma. Acta Ophthalmol Scand. 2007;85:579-580.
55. Char DH, Quivey JM, Castro JR, et al. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. Ophthalmology. 1993;100:1547-1554.